首页> 美国卫生研究院文献>other >Aflibercept Bevacizumab or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial

【2h】

Aflibercept Bevacizumab or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial

机译：AfliberceptBevacizumab或Ranibizumab治疗糖尿病性黄斑水肿：两年疗效比较随机临床试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeProvide 2-year efficacy, safety and treatment results comparing three anti-vascular endothelial growth factor (anti-VEGF) agents for center-involved diabetic macular edema (DME) utilizing a standardized follow-up and retreatment regimen.

机译：目的提供2年的疗效，安全性和治疗结果，并通过标准化的随访和再治疗方案比较三种抗血管内皮生长因子（anti-VEGF）药物治疗中心性糖尿病性黄斑水肿（DME）。

著录项

期刊名称 other
作者
John A. Wells; Adam R. Glassman; Allison R. Ayala; Lee M. Jampol; Neil M. Bressler; Susan B. Bressler; Alexander J. Brucker; Frederick L. Ferris; G. Robert. Hampton; Chirag Jhaveri; Michele Melia; Roy W. Beck;
展开▼
作者单位

展开▼
年(卷),期 -1(123),6
年度 -1
页码 1351–1359
总页数 19
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359) [J] . Shanmugam Mahesh P., Harshey Kaustubh B., Ramanjulu Rajesh, Ophthalmology . 2017,第1期

机译：Re：Wells等人：Aflibercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：两年的比较疗效随机临床试验（2016年眼科; 123：1351-1359）
2. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358) [J] . Tornambe Paul Ophthalmology . 2017,第3期

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：两年的比较有效性随机临床试验（2016年眼科; 123：1351-1358）
3. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359) REPLY [J] . Wells John A., Glassman Adam R., Ayala Allison R., Ophthalmology . 2017,第1期

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：对比疗效随机临床试验的两年结果（2016年眼科; 123：1351-1359）回复
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Structural and Vascular Changes Following Laser for Diabetic Macular Edema. [D] . Leontieva, Elena. 2016

机译：激光治疗糖尿病性黄斑水肿后的结构和血管变化。
6. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept Bevacizumab and Ranibizumab for Diabetic Macular Edema [O] . Adam R. Glassman, Danni Liu, Lee M. Jampol, -1

机译：比较AfliberceptBevacizumab和Ranibizumab治疗糖尿病性黄斑水肿的随机临床试验中血压和尿白蛋白-肌酐比值的变化
7. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359) [O] . Mahesh P. Shanmugam, Kaustubh B. Harshey, Rajesh Ramanjulu, 2017

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：对比有效性随机临床试验的两年结果（2016年眼科; 123：1351-1359）

Aflibercept Bevacizumab or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅